<DOC>
	<DOCNO>NCT01202214</DOCNO>
	<brief_summary>The purpose study describe safety tolerability single repeat oral dos GSK1440115 healthy volunteer .</brief_summary>
	<brief_title>Repeat Dose Safety Study Compound Treat Asthma</brief_title>
	<detailed_description>This study first administration GSK1440115 human . GSK1440115 urotensin II receptor antagonist develop treatment asthma . This two-part study evaluate safety , tolerability , pharmacokinetics single ( Part A ) repeat ( Part B ) oral dos GSK1440115 healthy adult male female ( non-child bearing potential ) subject . This study randomize , single-blind , placebo-controlled , dose escalation design . Part A evaluate single dose GSK1440115 . Part B evaluate repeat daily dose 7 day .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>1 . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . 2 . Male female 18 65 year age inclusive , time signing informed consent . 3 . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample simultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 147 pmol/L ) confirmatory ] . [ Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method Section 8.1 wish continue HRT study . Otherwise , must discontinue HRT allow confirmation postmenopausal status prior study enrollment . For form HRT , least 24 week elapse cessation therapy blood draw ; interval depend type dosage HRT . Following confirmation postmenopausal status , resume use HRT study without use contraceptive method . ] 4 . Male subject female partner childbearing potential must agree use one contraception method list Section 8.1 . This criterion must follow time first dose study drug completion Followup Period . 5 . Capable give write informed consent , include compliance requirement restriction list consent form . 6 . AST , ALT , alkaline phosphatase bilirubin less equal 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . 7 . QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . 1 . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month Screening 2 . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . 3 . A positive prestudy drug/alcohol screen . 4 . A positive test HIV antibody . 5 . Average systolic blood pressure &lt; 100 mmHg Screening . 6 . History regular alcohol consumption within 6 month study define : average weekly intake &gt; 21 unit male &gt; 14 unit female . One unit equivalent 8 g alcohol : halfpint ( ~240 ml ) beer , 1 glass ( 125 ml ) wine 1 ( 25 ml ) measure spirit . 7 . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . 8 . Use prescription nonprescription medication , vitamin , dietary herbal supplement ( include St John 's Wort ) within 7 day ( 14 day medication potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study drug , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . 9 . History sensitivity study medication , component thereof history drug allergy , opinion Investigator GSK Medical Monitor , contraindicate participation . 10 . Where participation study would result donation blood blood product excess 500 mL within 56 day period . 11 . Pregnant female determine positive serum urine hCG test Screening prior dosing . 12 . Lactating female . 13 . Unwillingness inability follow procedure outline protocol . 14 . Subject mentally legally incapacitate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2011</verification_date>
</DOC>